About the Animation:
The Mechanism of Action of KLS-13019 against CIPN toxicity has been published in the Journal of Molecular Neuroscience paper titled, “Knockdown siRNA Targeting the Mitochondrial Sodium-Calcium Exchanger-1 Inhibits the Protective Effects of Two Cannabinoids Against Acute Paclitaxel Toxicity"
KLS-13019 is Kannalife’s (a subsidiary of Neuropathix) leading proprietary, investigational CBD-like product for the potential treatment of a range of neurodegenerative and neuropathic pain disorders, including chemotherapy-induced peripheral neuropathy (CIPN). It has not yet been reviewed or approved for patient use by the U.S. Food and Drug Administration (FDA) or any other drug regulatory authority in the world.
CIPN is an adverse effect following receipt of any chemotherapy agent. There is no effective prevention strategy and treatment of established chronic CIPN is limited.* Existing treatment options primarily include anticonvulsants and antidepressants, as well as opioids in more severe cases.**
KLS-13019 has only been tested in CIPN involving m-NCX1 dysregulation and represents a potentially viable treatment alternative. Application of this proprietary molecule in other neurodegenerative and neuropathic pain conditions remains under investigation.
*Source: National Center for Biotechnology Information. Incidence, prevalence, and predictors of chemotherapy-induced peripheral neuropathy: a systematic review and meta-analysis. Accessed at ncbi.nlm.nih.gov/books/NBK291675/
**Source: Datamonitor Healthcare. Neuropathic Pain Market and Forecast Analysis to 2026. Accessed at pharmastore.informa.com/product/neuropathic-pain-market-forecast-analysis-2026/
Neuropathix Official Website: